Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

被引：33

作者：

Lima, Caio M. Rocha ^{[1
,2
]}

Bayraktar, Soley ^{[1
,2
]}

Flores, Aurea M. ^{[1
,2
]}

MacIntyre, Jessica ^{[1
,2
]}

Montero, Alberto ^{[1
,2
]}

Baranda, Joaquina C. ^{[3
]}

Wallmark, John ^{[4
]}

Portera, Chia ^{[5
]}

Raja, Rajiv ^{[5
]}

Stern, Howard ^{[5
]}

Royer-Joo, Stephanie ^{[5
]}

Amler, Lukas C. ^{[5
]}

机构：

[1] Univ Miami, Div Hematol Oncol, Miami, FL 33136 USA

[2] Univ Miami Hosp & Clin, Sylvester Comprehens Canc Ctr, Miami, FL USA

[3] Univ Kansas, Med Ctr, Dept Med Oncol, Kansas City, KS 66103 USA

[4] Associates Oncol Hematol PC, Rockville, MD USA

[5] Genentech Inc, San Francisco, CA 94080 USA

来源：

CANCER INVESTIGATION | 2012年 / 30卷 / 10期

关键词：

Drozitumab; Metastatic colorectal cancer; Apo2; ligand; Apoptosis; Toxicity; Efficacy; CLINICAL-TRIALS; CHEMOTHERAPY;

D O I：

10.3109/07357907.2012.732163

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

引用

页码：727 / 731

页数：5

共 50 条

[31] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
Muro, K.
Uetake, H.
Tsuchihara, K.
Shitara, K.
Yamazaki, K.
Ota, M.
Oki, E.
Sato, T.
Naitoh, T.
Komatsu, Y.
Kato, T.
Yamanaka, K.
Mori, I.
Soeda, J.
Hihara, M.
Yamanaka, T.
Akagi, K.
Ochiai, A.
Yoshino, T.
ANNALS OF ONCOLOGY, 2019, 30
[32] SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
Gibbs, Peter
Heinemann, Volker
Sharma, Navesh K.
Findlay, Michael P. N.
Ricke, Jens
Peeters, Marc
Perez, David
Robinson, Bridget Anne
Strickland, Andrew
Ferguson, Tom
Rodriguez, Javier
Kroening, Hendrik
Wolf, Ido
Ganju, Vinod
Walpole, Euan Thomas
Boucher, Eveline
Tichler, Thomas E.
Gebski, Val
Van Buskirk, Mark
Van Hazel, Guy A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[33] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
Zhou, Fuxiang
Wang Wen-bo
Xia, Ling
Dai, Jing
Wu, Han
Yang, Lei
Xiong, Zhiguo
Gong, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
[34] Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial
Emi, Y.
Yamanaka, T.
Muro, K.
Uetake, H.
Oki, E.
Takahashi, T.
Katayose, Y.
Yoshida, K.
Sakamoto, M.
Aishima, S.
Ishida, K.
Imura, J.
Unno, M.
Hyodo, I.
Tomita, N.
Sugihara, K.
Maehara, Y.
ANNALS OF ONCOLOGY, 2018, 29
[35] Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
Saltz, L.
Infante, J.
Schwartzberg, L.
Stephenson, J.
Rocha-Lima, C.
Galimi, F.
Dillingham, K.
Hsu, M.
Wiezorek, J.
Fuchs, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[36] BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Benson, Al B., III
Kiss, Igor
Bridgewater, John
Eskens, Ferry A. L. M.
Sasse, Carolyn
Vossen, Sandra
Chen, Jihong
Van Sant, Chip
Ball, Howard A.
Keating, Anne
Krivoshik, Andrew
CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5058 - 5067
[37] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
Kito, Yosuke
Satake, Hironaga
Taniguchi, Hiroya
Yamada, Takeshi
Horie, Yoshiki
Esaki, Taito
Denda, Tadamichi
Yasui, Hisateru
Izawa, Naoki
Masuishi, Toshiki
Moriwaki, Toshikazu
Mori, Keita
Yamazaki, Kentaro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 277 - 284
[38] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
Yosuke Kito
Hironaga Satake
Hiroya Taniguchi
Takeshi Yamada
Yoshiki Horie
Taito Esaki
Tadamichi Denda
Hisateru Yasui
Naoki Izawa
Toshiki Masuishi
Toshikazu Moriwaki
Keita Mori
Kentaro Yamazaki
Cancer Chemotherapy and Pharmacology, 2020, 86 : 277 - 284
[39] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
Hiroshi, Tamagawa
Kentaro, Yamazaki
Koichi, Suyama
Michio, Okabe
Kazuya, Suzuki
Nobuhiko, Seki
Kentaro, Kawakami
Mikio, Sato
Yasuo, Takahashi
Tomonori, Hirashima
Masahide, Ebi
Keisei, Taku
Toshio, Otsuji
Fumio, Tamura
Eiji, Shinozaki
Koji, Nakashima
Kensei, Yamaguchi
Masahiko, Ando
Satoshi, Morita
Narikazu, Boku
Ichinosuke, Hyodo
ANNALS OF ONCOLOGY, 2014, 25
[40] S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Yamada, Y.
Denda, T.
Gamoh, M.
Iwanaga, I.
Yuki, S.
Shimodaira, H.
Nakamura, M.
Yamaguchi, T.
Ohori, H.
Kobayashi, K.
Tsuda, M.
Kobayashi, Y.
Miyamoto, Y.
Kotake, M.
Shimada, K.
Sato, A.
Morita, S.
Takahashi, S.
Komatsu, Y.
Ishioka, C.
ANNALS OF ONCOLOGY, 2018, 29 (03) : 624 - 631

← 1 2 3 4 5 →